Stay updated on Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.
Latest updates to the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page
- Check4 days agoChange DetectedLocations section now lists Oregon as a study site, reflected in Revision: v3.3.3. The previous Oregon Locations and HHS Vulnerability Disclosure links were removed (v3.3.2).SummaryDifference0.2%
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded explicit PSA progression criteria (a ≥25% increase and ≥2 ng/mL above nadir, confirmed ≥3 weeks later) and a plan to plot Kaplan-Meier progression-free survival curves by subgroup, together with an updated estimated study completion date of 2026-06-30.SummaryDifference0.4%
- Check33 days agoChange DetectedThe Publications section description now indicates that publications are automatically filled from PubMed, and the page revision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%
- Check40 days agoChange DetectedRemoved the government funding lapse notice from the page, which previously warned that information may not be up to date and that operations could be interrupted.SummaryDifference0.4%
- Check54 days agoChange DetectedThe updated page shows minor layout/formatting adjustments to the Study Details page without changing core trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check83 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.SummaryDifference2%
Stay in the know with updates to Pembrolizumab for Metastatic Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Metastatic Prostate Cancer Clinical Trial page.